CA2555417A1 - Inhibition of fgf signaling - Google Patents
Inhibition of fgf signaling Download PDFInfo
- Publication number
- CA2555417A1 CA2555417A1 CA002555417A CA2555417A CA2555417A1 CA 2555417 A1 CA2555417 A1 CA 2555417A1 CA 002555417 A CA002555417 A CA 002555417A CA 2555417 A CA2555417 A CA 2555417A CA 2555417 A1 CA2555417 A1 CA 2555417A1
- Authority
- CA
- Canada
- Prior art keywords
- fgf
- sulf1
- exogenous
- fgfr1
- signaling
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 230000011664 signaling Effects 0.000 title claims abstract description 115
- 230000005764 inhibitory process Effects 0.000 title claims description 30
- 229920002971 Heparan sulfate Polymers 0.000 claims abstract description 108
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 claims abstract description 88
- 101150048283 SULF1 gene Proteins 0.000 claims abstract description 71
- 238000000034 method Methods 0.000 claims abstract description 67
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 33
- 101150021185 FGF gene Proteins 0.000 claims abstract description 28
- 239000000203 mixture Substances 0.000 claims abstract description 14
- 102100028072 Fibroblast growth factor 4 Human genes 0.000 claims abstract description 13
- ZEOWTGPWHLSLOG-UHFFFAOYSA-N Cc1ccc(cc1-c1ccc2c(n[nH]c2c1)-c1cnn(c1)C1CC1)C(=O)Nc1cccc(c1)C(F)(F)F Chemical compound Cc1ccc(cc1-c1ccc2c(n[nH]c2c1)-c1cnn(c1)C1CC1)C(=O)Nc1cccc(c1)C(F)(F)F ZEOWTGPWHLSLOG-UHFFFAOYSA-N 0.000 claims abstract 3
- 102100023593 Fibroblast growth factor receptor 1 Human genes 0.000 claims abstract 3
- 101710182386 Fibroblast growth factor receptor 1 Proteins 0.000 claims abstract 3
- 102100035290 Fibroblast growth factor 13 Human genes 0.000 claims abstract 2
- 101001060274 Homo sapiens Fibroblast growth factor 4 Proteins 0.000 claims abstract 2
- 210000004027 cell Anatomy 0.000 claims description 130
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical class OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims description 102
- 229960002897 heparin Drugs 0.000 claims description 76
- 229920000669 heparin Polymers 0.000 claims description 73
- 230000004913 activation Effects 0.000 claims description 32
- 230000009918 complex formation Effects 0.000 claims description 29
- -1 Sulf1-modified heparin compound Chemical class 0.000 claims description 21
- 230000000694 effects Effects 0.000 claims description 20
- 238000006471 dimerization reaction Methods 0.000 claims description 18
- 108091008794 FGF receptors Proteins 0.000 claims description 17
- 230000015572 biosynthetic process Effects 0.000 claims description 17
- 210000000130 stem cell Anatomy 0.000 claims description 17
- 102000052178 fibroblast growth factor receptor activity proteins Human genes 0.000 claims description 15
- 210000003716 mesoderm Anatomy 0.000 claims description 15
- 238000000338 in vitro Methods 0.000 claims description 11
- 238000004519 manufacturing process Methods 0.000 claims description 9
- 238000001727 in vivo Methods 0.000 claims description 7
- NHJSWORVNIOXIT-UHFFFAOYSA-N PD-166866 Chemical compound COC1=CC(OC)=CC(C=2C(=NC3=NC(N)=NC=C3C=2)NC(=O)NC(C)(C)C)=C1 NHJSWORVNIOXIT-UHFFFAOYSA-N 0.000 claims description 5
- CENHPXAQKISCGD-UHFFFAOYSA-N trioxathietane 4,4-dioxide Chemical group O=S1(=O)OOO1 CENHPXAQKISCGD-UHFFFAOYSA-N 0.000 claims description 5
- 230000007423 decrease Effects 0.000 claims description 4
- 108091054455 MAP kinase family Proteins 0.000 claims description 3
- 102000043136 MAP kinase family Human genes 0.000 claims description 3
- 239000003112 inhibitor Substances 0.000 claims description 3
- 230000001737 promoting effect Effects 0.000 claims description 3
- 230000004565 tumor cell growth Effects 0.000 claims description 3
- VEEGZPWAAPPXRB-BJMVGYQFSA-N (3e)-3-(1h-imidazol-5-ylmethylidene)-1h-indol-2-one Chemical compound O=C1NC2=CC=CC=C2\C1=C/C1=CN=CN1 VEEGZPWAAPPXRB-BJMVGYQFSA-N 0.000 claims description 2
- 229940121369 angiogenesis inhibitor Drugs 0.000 claims description 2
- 239000004037 angiogenesis inhibitor Substances 0.000 claims description 2
- 230000009467 reduction Effects 0.000 claims description 2
- 230000014399 negative regulation of angiogenesis Effects 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 abstract description 19
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 146
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 146
- 229940126864 fibroblast growth factor Drugs 0.000 description 145
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 85
- 241001465754 Metazoa Species 0.000 description 36
- 230000019635 sulfation Effects 0.000 description 31
- 238000005670 sulfation reaction Methods 0.000 description 31
- 108020003175 receptors Proteins 0.000 description 26
- 102000005962 receptors Human genes 0.000 description 26
- 230000014509 gene expression Effects 0.000 description 21
- 230000033115 angiogenesis Effects 0.000 description 20
- 210000002257 embryonic structure Anatomy 0.000 description 20
- 108090000623 proteins and genes Proteins 0.000 description 16
- 210000001519 tissue Anatomy 0.000 description 16
- 102000019149 MAP kinase activity proteins Human genes 0.000 description 15
- 108040008097 MAP kinase activity proteins Proteins 0.000 description 15
- 238000003556 assay Methods 0.000 description 15
- 239000003446 ligand Substances 0.000 description 13
- 239000012528 membrane Substances 0.000 description 13
- 229920002683 Glycosaminoglycan Polymers 0.000 description 12
- 230000006698 induction Effects 0.000 description 12
- 210000004379 membrane Anatomy 0.000 description 12
- 239000011324 bead Substances 0.000 description 11
- 230000003993 interaction Effects 0.000 description 11
- 210000004204 blood vessel Anatomy 0.000 description 10
- 108020004999 messenger RNA Proteins 0.000 description 10
- 230000026731 phosphorylation Effects 0.000 description 10
- 238000006366 phosphorylation reaction Methods 0.000 description 10
- 102000004169 proteins and genes Human genes 0.000 description 10
- 241000269370 Xenopus <genus> Species 0.000 description 9
- 230000005012 migration Effects 0.000 description 9
- 238000013508 migration Methods 0.000 description 9
- 238000001262 western blot Methods 0.000 description 9
- 102000004190 Enzymes Human genes 0.000 description 8
- 108090000790 Enzymes Proteins 0.000 description 8
- 206010028980 Neoplasm Diseases 0.000 description 8
- 102000013814 Wnt Human genes 0.000 description 8
- 108050003627 Wnt Proteins 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 230000006870 function Effects 0.000 description 8
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 7
- 230000004663 cell proliferation Effects 0.000 description 7
- 230000004069 differentiation Effects 0.000 description 7
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate group Chemical group S(=O)(=O)([O-])[O-] QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 7
- 102000008055 Heparan Sulfate Proteoglycans Human genes 0.000 description 6
- 108090000054 Syndecan-2 Proteins 0.000 description 6
- 201000011510 cancer Diseases 0.000 description 6
- 230000007547 defect Effects 0.000 description 6
- 230000018109 developmental process Effects 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 210000001161 mammalian embryo Anatomy 0.000 description 6
- 230000001404 mediated effect Effects 0.000 description 6
- 230000035772 mutation Effects 0.000 description 6
- 230000002265 prevention Effects 0.000 description 6
- 230000019491 signal transduction Effects 0.000 description 6
- 230000007781 signaling event Effects 0.000 description 6
- 230000001629 suppression Effects 0.000 description 6
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 5
- 230000024245 cell differentiation Effects 0.000 description 5
- 230000001419 dependent effect Effects 0.000 description 5
- 230000002255 enzymatic effect Effects 0.000 description 5
- MSWZFWKMSRAUBD-IVMDWMLBSA-N glucosamine group Chemical group OC1[C@H](N)[C@@H](O)[C@H](O)[C@H](O1)CO MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 5
- 230000003834 intracellular effect Effects 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 4
- 239000002299 complementary DNA Substances 0.000 description 4
- 125000000600 disaccharide group Chemical group 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 238000011068 loading method Methods 0.000 description 4
- 238000000159 protein binding assay Methods 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 3
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 3
- 108090000381 Fibroblast growth factor 4 Proteins 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 241000286209 Phasianidae Species 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 210000003981 ectoderm Anatomy 0.000 description 3
- 210000002308 embryonic cell Anatomy 0.000 description 3
- 210000002744 extracellular matrix Anatomy 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 230000009131 signaling function Effects 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 238000011144 upstream manufacturing Methods 0.000 description 3
- 229920000936 Agarose Polymers 0.000 description 2
- 241000271566 Aves Species 0.000 description 2
- 108091016585 CD44 antigen Proteins 0.000 description 2
- XTEGARKTQYYJKE-UHFFFAOYSA-M Chlorate Chemical compound [O-]Cl(=O)=O XTEGARKTQYYJKE-UHFFFAOYSA-M 0.000 description 2
- 102000044168 Fibroblast Growth Factor Receptor Human genes 0.000 description 2
- DHCLVCXQIBBOPH-UHFFFAOYSA-N Glycerol 2-phosphate Chemical compound OCC(CO)OP(O)(O)=O DHCLVCXQIBBOPH-UHFFFAOYSA-N 0.000 description 2
- 239000012981 Hank's balanced salt solution Substances 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101150018665 MAPK3 gene Proteins 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 102000008300 Mutant Proteins Human genes 0.000 description 2
- 108010021466 Mutant Proteins Proteins 0.000 description 2
- 108091000080 Phosphotransferase Proteins 0.000 description 2
- 102000001708 Protein Isoforms Human genes 0.000 description 2
- 108010029485 Protein Isoforms Proteins 0.000 description 2
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 2
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 2
- 230000010799 Receptor Interactions Effects 0.000 description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
- 239000006180 TBST buffer Substances 0.000 description 2
- 101001023030 Toxoplasma gondii Myosin-D Proteins 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 210000000625 blastula Anatomy 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 210000000692 cap cell Anatomy 0.000 description 2
- 230000036755 cellular response Effects 0.000 description 2
- 239000003636 conditioned culture medium Substances 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 238000012866 crystallographic experiment Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 230000009977 dual effect Effects 0.000 description 2
- 235000013601 eggs Nutrition 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 230000004068 intracellular signaling Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000033667 organ regeneration Effects 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- 102000020233 phosphotransferase Human genes 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 230000002028 premature Effects 0.000 description 2
- 230000009711 regulatory function Effects 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 210000002023 somite Anatomy 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000017423 tissue regeneration Effects 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 206010008723 Chondrodystrophy Diseases 0.000 description 1
- 101000601610 Drosophila melanogaster Heparan sulfate N-sulfotransferase Proteins 0.000 description 1
- 101100017779 Drosophila melanogaster Hs2st gene Proteins 0.000 description 1
- 206010013883 Dwarfism Diseases 0.000 description 1
- 241000027355 Ferocactus setispinus Species 0.000 description 1
- 108090000386 Fibroblast Growth Factor 1 Proteins 0.000 description 1
- 102000003971 Fibroblast Growth Factor 1 Human genes 0.000 description 1
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102100029001 Heparan sulfate 2-O-sulfotransferase 1 Human genes 0.000 description 1
- 101710096984 Heparan sulfate 2-O-sulfotransferase 1 Proteins 0.000 description 1
- 101000820630 Homo sapiens Extracellular sulfatase Sulf-1 Proteins 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 101000844802 Lacticaseibacillus rhamnosus Teichoic acid D-alanyltransferase Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 108091030071 RNAI Proteins 0.000 description 1
- 238000010240 RT-PCR analysis Methods 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 102000005262 Sulfatase Human genes 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 108700019432 Xenopus FGF4 Proteins 0.000 description 1
- 241000269368 Xenopus laevis Species 0.000 description 1
- 208000008919 achondroplasia Diseases 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000002491 angiogenic effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- 230000007321 biological mechanism Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 210000002449 bone cell Anatomy 0.000 description 1
- 230000008468 bone growth Effects 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 210000003711 chorioallantoic membrane Anatomy 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000037011 constitutive activity Effects 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 230000006862 enzymatic digestion Effects 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 230000008622 extracellular signaling Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000009368 gene silencing by RNA Effects 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 102000050715 human SULF1 Human genes 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 201000010072 hypochondroplasia Diseases 0.000 description 1
- 238000005462 in vivo assay Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000031146 intracellular signal transduction Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 108020001756 ligand binding domains Proteins 0.000 description 1
- 210000000982 limb bud Anatomy 0.000 description 1
- 239000012160 loading buffer Substances 0.000 description 1
- 230000002132 lysosomal effect Effects 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 238000000329 molecular dynamics simulation Methods 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 210000001020 neural plate Anatomy 0.000 description 1
- 210000000276 neural tube Anatomy 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 230000035778 pathophysiological process Effects 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 238000000059 patterning Methods 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 1
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 239000012723 sample buffer Substances 0.000 description 1
- 210000003625 skull Anatomy 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 108060007951 sulfatase Proteins 0.000 description 1
- 125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 201000003896 thanatophoric dysplasia Diseases 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 230000005747 tumor angiogenesis Effects 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 230000008189 vertebrate development Effects 0.000 description 1
- 230000007998 vessel formation Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/727—Heparin; Heparan
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/06—Sulfuric ester hydrolases (3.1.6)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Dermatology (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US54444904P | 2004-02-13 | 2004-02-13 | |
| US60/544,449 | 2004-02-13 | ||
| PCT/US2005/004682 WO2005079390A2 (en) | 2004-02-13 | 2005-02-11 | Inhibition of fgf signaling |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2555417A1 true CA2555417A1 (en) | 2005-09-01 |
Family
ID=34886037
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002555417A Abandoned CA2555417A1 (en) | 2004-02-13 | 2005-02-11 | Inhibition of fgf signaling |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US7968527B2 (enExample) |
| EP (1) | EP1742961A4 (enExample) |
| JP (1) | JP2007522243A (enExample) |
| CA (1) | CA2555417A1 (enExample) |
| WO (1) | WO2005079390A2 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200914044A (en) * | 2007-07-12 | 2009-04-01 | Daiichi Sankyo Co Ltd | Anti human Sulf1 antibody |
| WO2009011892A2 (en) * | 2007-07-18 | 2009-01-22 | Boston Biomedical Research Institute | Use of suif proteins and heparan sulfate in gdnf-dependent neural innervation and protection |
| WO2010003023A2 (en) * | 2008-07-01 | 2010-01-07 | Zacharon Pharmaceuticals, Inc. | Heparan sulfate inhibitors |
| US20120301463A1 (en) | 2009-09-30 | 2012-11-29 | President And Fellows Of Harvard College | Methods for Modulation of Autophagy Through the Modulation of Autophagy-Enhancing Gene Products |
| JP5784296B2 (ja) * | 2010-10-01 | 2015-09-24 | 学校法人 創価大学 | 神経細胞の製造方法及び神経細胞分化促進剤 |
| KR20150123250A (ko) | 2013-03-06 | 2015-11-03 | 제넨테크, 인크. | 암 약물 내성의 치료 및 예방 방법 |
| JP2017517552A (ja) | 2014-06-13 | 2017-06-29 | ジェネンテック， インコーポレイテッド | 抗癌剤耐性の治療及び防止方法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1206234A4 (en) * | 1999-06-03 | 2005-06-01 | Jessie L S Au | METHODS AND COMPOSITIONS FOR MODULATING PROLIFERATION AND CELL DEATH |
| US7129072B1 (en) * | 1999-08-30 | 2006-10-31 | New York University | Crystal of fibroblast growth factor receptor 1 in complex with fibroblast growth factor |
| US20030147875A1 (en) * | 2000-12-27 | 2003-08-07 | Steven Rosen | Sulfatases and methods of use thereof |
| WO2003012053A2 (en) * | 2001-08-01 | 2003-02-13 | New York University | Identification of receptor and heparin binding sites in fgf4 by structure-based mutagenesis |
-
2005
- 2005-02-11 US US11/057,390 patent/US7968527B2/en not_active Expired - Fee Related
- 2005-02-11 CA CA002555417A patent/CA2555417A1/en not_active Abandoned
- 2005-02-11 WO PCT/US2005/004682 patent/WO2005079390A2/en not_active Ceased
- 2005-02-11 EP EP05713533A patent/EP1742961A4/en not_active Withdrawn
- 2005-02-11 JP JP2006553327A patent/JP2007522243A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US7968527B2 (en) | 2011-06-28 |
| EP1742961A2 (en) | 2007-01-17 |
| WO2005079390A2 (en) | 2005-09-01 |
| EP1742961A4 (en) | 2009-07-15 |
| US20050227921A1 (en) | 2005-10-13 |
| WO2005079390A3 (en) | 2006-12-14 |
| JP2007522243A (ja) | 2007-08-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Poulain et al. | Heparan sulfate proteoglycans: a sugar code for vertebrate development? | |
| Barnea et al. | Receptor tyrosine phosphatase beta is expressed in the form of proteoglycan and binds to the extracellular matrix protein tenascin. | |
| Stachowiak et al. | Integrative nuclear FGFR1 signaling (INFS) as a part of a universal “feed‐forward‐and‐gate” signaling module that controls cell growth and differentiation | |
| Brodie et al. | Protein kinase C-ε plays a role in neurite outgrowth in response to epidermal growth factor and nerve growth factor in PC12 cells | |
| Dailey et al. | Mechanisms underlying differential responses to FGF signaling | |
| Ford‐Perriss et al. | Localisation of specific heparan sulfate proteoglycans during the proliferative phase of brain development | |
| Grant et al. | Cyclin‐dependent protein kinase 5 (Cdk5) and the regulation of neurofilament metabolism | |
| Izvolsky et al. | Heparan sulfate–FGF10 interactions during lung morphogenesis | |
| Kubota et al. | Chemotactic migration of mesencephalic neural crest cells in the mouse | |
| Cheng et al. | PDGFs protect hippocampal neurons against energy deprivation and oxidative injury: evidence for induction of antioxidant pathways | |
| Bourguignon et al. | Hyaluronan‐CD44 interaction stimulates Rac1 signaling and PKNγ kinase activation leading to cytoskeleton function and cell migration in astrocytes | |
| Tanga et al. | The PTN‐PTPRZ signal activates the AFAP1L2‐dependent PI3K‐AKT pathway for oligodendrocyte differentiation: targeted inactivation of PTPRZ activity in mice | |
| Pathre et al. | PTP1B regulates neurite extension mediated by cell‐cell and cell‐matrix adhesion molecules | |
| Mason et al. | SOST and DKK: antagonists of LRP family signaling as targets for treating bone disease | |
| Cragnolini et al. | Nerve growth factor induces cell cycle arrest of astrocytes | |
| Sanchez et al. | Regulation of a site-specific phosphorylation of the microtubule-associated protein 2 during the development of cultured neurons | |
| Finburgh et al. | Role of FGF10/FGFR2b signaling in homeostasis and regeneration of adult lacrimal gland and corneal epithelium proliferation | |
| Shannon et al. | Chondroitin sulfate proteoglycans are required for lung growth and morphogenesis in vitro | |
| Eckert et al. | Neuregulin‐1β and neuregulin‐1α differentially affect the migration and invasion of malignant peripheral nerve sheath tumor cells | |
| US7968527B2 (en) | Inhibition of FGF signaling | |
| Kaucká et al. | Post‐translational modifications regulate signalling by Ror1 | |
| Tringali et al. | NEU4L sialidase overexpression promotes β‐catenin signaling in neuroblastoma cells, enhancing stem‐like malignant cell growth | |
| Gao et al. | Fluoride regulates the expression of extracellular matrix HSPG and related signaling pathways FGFR3 and Ihh/PTHrP feedback loop during endochondral ossification | |
| Mundy et al. | HhAntag, a hedgehog signaling antagonist, suppresses chondrogenesis and modulates canonical and non‐canonical BMP signaling | |
| Buczek‐Thomas et al. | Heparan sulfate depletion within pulmonary fibroblasts: implications for elastogenesis and repair |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Dead |
Effective date: 20130211 |